Description
Despite PARKIN mutations causing early-onset PD in humans, multiple mouse models show no motor impairment or neurodegeneration. This species difference undermines translational research and suggests unknown compensatory mechanisms or fundamental differences in PARKIN function between humans and mice.
Gap type: contradiction Source paper: PARKIN is not required to sustain OXPHOS function in adult mammalian tissues. (None, None, PMID:38684669)
Resolution criteria
Resolution requires: (1) Systematic comparison of PARKIN-/- mice vs. PARKIN mutation patient iPSC-derived dopaminergic neurons under identical mitochondrial stressors (CCCP, rotenone, MPTP) identifies >=3 mouse-specific compensatory mechanisms (upregulated proteins/pathways >=2-fold, FDR<0.05) absent in human neurons, including at minimum one mitophagy-related pathway (BNIP3L/NIX upregulation confirmed by WB); (2) PARKIN knockout in human iPSC-derived dopaminergic neurons shows >=30% greater mitochondrial dysfunction (Seahorse OCR, MMP by TMRE) and >=20% reduced viability under CCCP stress vs. matched controls, demonstrating human-specific vulnerability; (3) Genetic humanization: CRISPR introduction of one mouse-specific compensatory factor into human neurons partially rescues (>=40% reduction in cell death) under mitochondrial stress, confirming it as a mechanistic explanation for the translational gap. Behavioral phenotype comparisons alone without cross-species molecular mechanism data are insufficient.